MTOR and ovarian cancer: Similarly, a study in a large panel of ovarian cancer cell lines identified a link between K‐Ras/BRAF mutation status and resistance to the dual PI3K/mTOR inhibitor, PF‐04691502 (Sheppard et al., 2013).